300147 Xiangxue Pharmaceutical
- 6.20
- -0.17-2.67%
Xiangxue Pharmaceutical News
Xiangxue Pharmaceutical Co.,Ltd. (SZSE:300147) Looks Inexpensive After Falling 39% But Perhaps Not Attractive Enough
While Xiangxue PharmaceuticalLtd (SZSE:300147) Shareholders Have Made 28% in 1 Year, Increasing Losses Might Now Be Front of Mind as Stock Sheds 9.2% This Week
Xiangxue Pharmaceuticals: Semi-Annual Report 2024
Xiangxue Pharmaceuticals: 2024 Semi-Annual Report Summary
Xiangxue Pharmaceutical (300147.SZ) released its performance for the first half of the year, with a net loss of 0.135 billion yuan, and the loss expanded.
Xiangxue Pharmaceutical (300147.SZ) released its 2024 interim report, with revenue of 1.097 billion yuan...
Xiangxue Pharmaceutical (300147.SZ): Net loss of 0.135 billion yuan in the first half of the year, with an expanded loss compared to the same period last year.
Xiangxue Pharmaceutical (300147.SZ) announced its semi-annual report for 2024, with operating revenue of 1.097 billion yuan, a 8.72% decrease compared to the same period last year; net income attributable to shareholders of the listed company was -0.135 billion yuan, with an increased loss compared to the same period last year; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -0.108 billion yuan; basic earnings per share was -0.2 yuan.
Xiangxue Pharmaceutical Co.,Ltd.'s (SZSE:300147) Price Is Right But Growth Is Lacking After Shares Rocket 25%
The function of xiangxue pharmaceutical (300147.SZ) product Huoxiang Zhengqi mixture is to release exterior and transform dampness, regulate qi and harmonize the middle burner.
Xiangxue Pharmaceutical (300147.SZ) stated on its investor interaction platform on July 31st that the company's product, Huoxiang Zhengqi Oral Liquid, functions to disperse exterior pathogenic factors and resolve dampness, regulate qi and harmonize the middle. It is used for summer dampness cold, headache, body heaviness and chest tightness, or cold and fever with abdominal distension, vomiting, and diarrhea.
A-share noon report: Shanghai Composite Index rose 1.79%, Chinext Price Index rose 3.33%, nearly 5000 stocks rose! Brokerage stocks surged across the board.
As of noon closing, the Shanghai Composite Index rose 1.79% to 2930.8 points, the Shenzhen Component Index rose 2.96%, and the chinext price index rose 3.33%. Nearly 5000 stocks have risen.
Xiangxue Pharmaceutical (300147.SZ) intends to transfer 51% of the equity of its subsidiary Peking Xiangxue.
Xiangxue Pharmaceutical (300147.SZ) announced on July 19 that in order to further integrate resources, improve overall operation level, and orderly resolve corporate debt risks based on strategic planning and business development, Guangzhou Xiangxue Pharmaceutical Co., Ltd. has signed an equity transfer agreement with Beijing Liuguitang Enterprise Management Technology Co., Ltd. (referred to as "Beijing Liuguitang"), transferring 51% equity of its holding subsidiary Beijing Xiangxue Pharmaceutical Biotechnology Co., Ltd. (referred to as "Beijing Xiangxue") at a price of 23.868 million yuan.
Xiangxue Pharmaceutical (300147.SZ) achieved stable growth of revenue in 2023, with revenue growth of over 100% in the core business of Chinese patent medicine.
On July 16th, Gelonghui reported that Xiangxue Pharmaceutical (300147.SZ) stated on the investor interaction platform that with the continuous deepening of medical reform and the continuous promotion of relevant policies by the country, the pharmaceutical industry is undergoing systematic governance across the entire field, chain, and coverage. Facing various unexpected challenges such as the complex external environment, heavy internal debt burden, and large operational pressure, the company always puts product quality at the forefront of corporate development, actively responds to challenges, vigorously explores new markets, promotes the development of core business, and achieves stable revenue growth in 2023, with revenue growth in the core business of Chinese patent medicine sector.
Xiangxue Pharmaceutical (300147.SZ): The main research direction in the forefront of biotechnology and pharmaceutical R&D is T cell immunotherapy technology. The main products include TAEST16001, TAEST1901, etc.
On July 15th, GeLongHui reported that Xiangxue Pharmaceutical (300147.SZ) stated on an investor interaction platform that the company's main research direction in the forefront of biotechnology and pharmaceutical research and development is T-cell immunotherapy technology. The main products include TAEST16001, TAEST1901, etc. The TAEST16001 injection development project is mainly used to treat synovial sarcoma and is currently in the phase II clinical research stage of new drug registration clinical trials, which is being systematically promoted. The TAEST1901 injection development project is mainly used to treat primary liver cancer and is currently in the stage of initiating phase I clinical research.
Xiangxue Pharmaceutical (300147.SZ): Xiangxue antiviral oral solution has the effects of clearing heat and dampness, cooling blood and detoxification.
On June 28th, Gelunhui reported that Xiangxue Pharmaceutical (300147.SZ) stated on the investor interactive platform that its Xiangxue Anti-Virus Oral Liquid has the functions of clearing hotness and dampness, cooling blood and detoxification, and is widely used clinically to treat diseases such as cold, flu, upper respiratory tract infection, and mumps virus.
Xiangxue Pharmaceutical (300147.SZ) has established traditional Chinese medicine production bases in Ningxia, Sichuan, Yunnan, Guangdong and other places.
On June 26th, Gelon Hui reported that Xiangxue Pharmaceutical (300147.SZ) develops, produces and sells modern traditional Chinese medicine and Chinese patent medicine. Its brand "Xiangxue" was awarded the China Famous Trademark. Its main products are famous brand products in Guangdong Province, which have a great influence in the southern and even national markets. The company has established Chinese herbal medicine production bases in Ningxia, Sichuan, Yunnan, Guangdong and other places, utilizing local abundant Chinese herbal medicine resources to establish processing bases and Chinese herbal medicine trading markets for the production, cultivation, harvesting, and processing of Chinese herbal medicine.
Xiangxue Pharmaceutical (300147.SZ): Xiangxue Anti-Virus Oral Liquid has the functions of clearing heat, removing dampness, cooling blood and detoxifying.
Xiangxue Pharmaceutical (300147.SZ) stated on the investor interaction platform that the company's chinese patent medicine main products include antiviral oral liquid, Juhong series (phlegm cough oral liquid, granule, decoction, pear paste), Banlangen granule, etc. Xiangxue antiviral oral liquid has the efficacy of clearing heat and dampness, cooling blood and detoxification. It is widely used in the treatment of diseases such as cold, flu, upper respiratory tract infection, mumps, viral conjunctivitis, and hand, foot and mouth disease. The company's Juhong phlegm cough liquid is heavily used in the precious traditional chinese medicine materials of Lingnan local name "Huajuhong", and is processed with bitter almond, white front, honey Hundred Department, Wuweizi to become "warm and transform cold phlegm".
Xiangxue Pharmaceutical (300147.SZ): Xiangxue Nanya intends to transfer assets of Deqing County Nanya Industrial Park project to Xingshun Agriculture for 88.04 million yuan.
Xiangxue Pharmaceutical (300147.SZ) announced on June 21 that, in order to further revitalize assets, improve asset liquidity and utilization efficiency, resolve debt disputes, its subsidiary Guangdong Xiangxue Southern Medicine Development Co., Ltd. (hereinafter referred to as "Xiangxue South Medicine" or "Party A") has signed an Asset Transfer Agreement for the Nanyao Industrial Park Project in Deqing County with Deqingyuan Management Bureau of Zhaoqing High-tech Zone (hereinafter referred to as "Party B") and Xingshun Agriculture Development Co., Ltd. of Deqing County (hereinafter referred to as "Xingshun Agriculture" or "Party C").
Analysis of BT Financial Report: Xiangxue Pharmaceutical's 2024 Q1 financial report: Challenges and Opportunities Coexist.
Xiangxue Pharmaceutical (stock code: 300147) is a company specializing in the research and production of traditional Chinese medicine, committed to promoting innovation and high-quality development of the traditional Chinese medicine industry. With the support of national policies, the company actively responds to the call of revitalizing and developing traditional Chinese medicine, constantly improves the quality management of traditional Chinese medicinal materials and the regulatory level of traditional Chinese medicine preparations. Xiangxue Pharmaceutical focuses on the innovation of traditional Chinese medicine research and development, optimizes the evaluation and approval mechanism of traditional Chinese medicine, improves the standard management level of traditional Chinese medicine, and actively participates in the globalization cooperation of traditional Chinese medicine regulation. Faced with the challenges of the pharmaceutical industry, the company strives to maintain competitiveness in the mark
Xiang Xue Pharmaceutical (300147.SZ): TCR-T and CAR-T are both adjuvant immune cell treatments
Gelonghui, May 11 | Xiangxue Pharmaceutical (300147.SZ) said on the interactive platform that TCR-T and CAR-T are both secondary immune cell treatments, that is, immune cells are isolated from cancer patients, genetically modified and amplified in vitro, and then transported back to the patient's body, but their mechanisms for recognizing antigens are quite different. CAR-T cells use antibody fragments that bind to specific antigens on the surface of cancer cells. TCR-T cells can recognize tumor-specific antigens from the surface of cell membranes or from within cells, and can target most tumor-specific antigens, especially those within tumor cells. So TC
Strong Week for Xiangxue PharmaceuticalLtd (SZSE:300147) Shareholders Doesn't Alleviate Pain of Three-year Loss
Xiangxue Pharmaceutical (300147.SZ) announced first-quarter results, changing profit to loss of 35.66 million yuan
Xiangxue Pharmaceutical (300147.SZ) released its report for the first quarter of 2024. The company's revenue was 5.69...
Analysis
Price Target
No Data
No Data